Takeda (NYSE: TAK) and Protagonist Therapeutics (NASDAQ: PTGX) announced Friday August 28, 2026 FDA approval of Mimrylo (rusfertide, a first-in-class subcutaneous synthetic hepcidin mimetic peptide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare BCR-ABL-negative myeloproliferative neoplasm in which uncontrolled red blood cell production drives increased thrombotic risk. Approval was based on the Phase 3 VERIFY trial (n=293) in which 76.9% of patients on rusfertide plus standard of care were phlebotomy-free through Week 32 versus 32.9% on placebo plus standard of care, with statistically significant improvements in hematocrit control and patient-reported fatigue and symptom burden. Adverse events were generally low-grade and included localized injection-site reactions (55.9%), anemia (15.9%), and fatigue (15.2%). Mimrylo will be commercialized by Takeda under the 2024 worldwide license and collaboration agreement with Protagonist and will ship within 48 hours. Jefferies analysts project peak sales potential of $2 billion. The mechanism (mimicking the natural iron-regulator hepcidin to constrain iron availability for erythropoiesis) is the first commercial validation of the hepcidin mimetic peptide class after more than a decade of academic development.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced Monday evening August 18, 2026 that the registrational Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) met the FDA-agreed-upon primary endpoint with a 55% reduction in the composite rate of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events versus placebo (p=0.000003). The trial enrolled 78 participants with PBH following Roux-en-Y gastric bypass surgery, randomized 3:2 to avexitide 90 mg once-daily subcutaneous injection or placebo for 16 weeks across 21 US sites. All secondary endpoints were met: consistent, highly statistically significant, and clinically substantial reductions in Level 2 events by self-monitoring of blood glucose (SMBG), Level 2 events by continuous glucose monitoring (CGM), and Level 3 hypoglycemic events. Avexitide was generally well-tolerated with a favorable safety profile. Mechanism: avexitide is exendin (9-39), a 30-amino-acid peptide that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in the reconfigured gastrointestinal anatomy after Roux-en-Y gastric bypass. Amylyx plans to submit a New Drug Application (NDA) to the FDA by end of 2026 with potential commercial launch in 2027 if approved. If approved, avexitide would be the first FDA-approved therapy for post-bariatric hypoglycemia (which has no currently approved drug therapy) and the first Phase 3 success for a GLP-1 receptor antagonist mechanism (the mechanistic opposite of the semaglutide/tirzepatide agonist class).
Amylyx Pharmaceuticals (NASDAQ: AMLX) is on track for the registrational Phase 3 LUCIDITY trial top-line data readout in late August or early September 2026. Trial status: the last participant completed the final study visit in the 16-week double-blind period. Trial design: 78 patients with post-bariatric hypoglycemia (PBH) enrolled across 21 US sites and randomized 3:2 to avexitide 90 mg subcutaneous once daily or placebo for 16 weeks. Primary endpoint (agreed with the FDA): reduction in the composite of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events through Week 16. The trial design was informed by data from five prior clinical trials of avexitide in post-bariatric hypoglycemia that consistently showed statistically significant reductions in Level 2 and Level 3 hypoglycemic events. Avexitide is exendin (9-39), a peptide GLP-1 receptor antagonist that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in patients following Roux-en-Y gastric bypass surgery. If positive, commercial launch of avexitide is anticipated in 2027 for the indication that has no currently approved drug therapy. LUCIDITY is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism.
Amylyx Pharmaceuticals (NASDAQ: AMLX) confirmed on the August 6, 2026 Q2 2026 earnings call that top-line data from the registrational Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia will read out in late August or early September 2026. Avexitide (formerly XOMA 358) is exendin (9-39), a peptide GLP-1 receptor antagonist: a 30-amino-acid peptide that binds the GLP-1 receptor without activating it, blocking endogenous GLP-1 signaling. This is the mechanistic opposite of semaglutide, tirzepatide, and the other GLP-1 receptor agonists. Post-bariatric hypoglycemia (PBH) is a serious complication of Roux-en-Y gastric bypass surgery affecting roughly 8% of patients long-term and manifesting as postprandial hypoglycemia (dangerously low blood sugar after meals) driven by excessive GLP-1 signaling in the reconfigured GI anatomy. Avexitide blocks GLP-1 receptor activation to normalize postprandial glucose. Q2 2026 EPS of -$0.39 missed the -$0.35 consensus by $0.04 (11% below forecast). The LUCIDITY readout is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism. If positive, avexitide would represent a first-in-class approved therapy for post-bariatric hypoglycemia, an indication with no currently approved drug therapy.